MedTrace Logo

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis

NCT05265910 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2022-05-03

No results posted yet for this study

Summary

This is a single-center, randomized, double-masked, parallel study. In this clinical study, the efficacy comparison between Pataday® Once Daily Relief Extra Strength and Claritin® Tablets 24-Hour will be made using the Ora-CAC model, a validated clinical model accepted by regulatory agents for assessing the efficacy of products on the signs and symptoms of allergic conjunctivitis.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

olopatadine hydrochloride ophthalmic solution 0.7%

Pataday® Once Daily Relief Extra Strength (eyedrop)

DRUG

loratadine 10 mg

Claritin® Tablets 24-Hour (tablet)

DRUG

Tears Naturale

Tears Naturale® II (eyedrop)

DRUG

Placebo

Placebo tablet (tablet)

Sponsors & Collaborators

  • Andover Research Eye Institute

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-14
Primary Completion
2022-04-23
Completion
2022-04-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05265910 on ClinicalTrials.gov